The state of California has secured a $69 million settlement with Teva, which allegedly entered into collusive pay-for-delay agreements with generic competitors.
California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.
Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.
Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.
US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales.
Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.
The US Food and Drug Administration last week approved nine applications for the first generic versions of Pfizer’s Lyrica.
The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.
Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley.